United States Acral Lentiginous Melanoma Treatment Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Global Acute Acral Lentiginous Melanoma Treatment Market is growing at a CAGR of 3% during the forecast period 2024-2031.

Key Development:

United States: Recent Industry Developments

✅ In July 2025, the SUPRAME Phase 3 trial commenced in the U.S. and Germany, enrolling patients with unresectable or metastatic melanoma, including those with ALM. Participants are receiving either the IMA203 regimen or investigator's choice of approved therapies.

✅ In June 2025, the CAP 03-NEO Phase II trial reported promising neoadjuvant treatment results for patients with resectable stage II/III ALM, indicating potential advancements in early-stage treatment strategies.

✅ In April 2025, researchers at Moffitt Cancer Center presented findings at AACR 2025, demonstrating that blocking nitrosylation could enhance treatment efficacy for aggressive melanoma subtypes, including ALM.

Japan: Recent Industry Developments

✅ In May 2025, a study reviewed the pathogenesis, progression, and management of ALM, providing insights into potential therapeutic targets and treatment approaches in the Japanese context.

✅ In April 2025, a study discussed new insights into the immune and genomic landscape of ALM, highlighting potential areas for therapeutic intervention in Japan.

✅ In March 2025, a study evaluated surgical modalities for stage 0 to stage II ALM, providing data on treatment efficacy and outcomes in the Japanese population.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/acral-lentiginous-melanoma-treatment-market?sb

Recent Mergers and Acquisitions:

United States: Recent M&A Developments

✅ In July 2025, IO Biotech initiated a pivotal Phase 3 trial (IOB-013/KN-D18) for its cancer vaccine Cylembio® in combination with KEYTRUDA® for advanced melanoma. The trial is progressing as planned, with results expected in Q3 2025.

✅ In March 2025, Replimune's RP1 melanoma therapy neared an FDA decision, with a PDUFA date set for July 2025. The company is preparing its commercial infrastructure for a potential launch.

✅ In 2025, Bristol-Myers Squibb announced the acquisition of a biotech firm specializing in novel cancer therapies, including compounds targeting various melanoma subtypes. This acquisition reflects the company's strategy to bolster its oncology pipeline, particularly in addressing niches like acral lentiginous melanoma.

Japan: Recent M&A Developments

✅ In 2025, strategic mergers and acquisitions are shaping the landscape of the Acral Lentiginous Melanoma treatment market in Japan. Key pharmaceutical players are acquiring smaller biotech firms with promising ALM-focused therapies to enhance their product portfolios and market presence.

Key Players:

=> Genentech Inc., Global Calcium Pvt Ltd., Sun Pharmaceutical Industries Limited, F. Hoffmann-La Roche Ltd, Daiichi Sankyo Company, Limited, Novartis AG, Dr. Reddy's Laboratories, Array BioPharma Inc., Bristol-Myers Squibb Company, and Aetos Pharma Private Limited among others.

Growth Forecast Projected:

The Global Acral Lentiginous Melanoma Treatment Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Acral Lentiginous Melanoma Treatment Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=acral-lentiginous-melanoma-treatment-market

Key Segments:

➥ By Treatment: KIT inhibitors, BRAF inhibitors, Surgery, Others

➥ By End-User: Hospital, Oncology Centers, Ambulatory Surgical Centers, Others

Regional Analysis for Acral Lentiginous Melanoma Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Acral Lentiginous Melanoma Treatment producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Acral Lentiginous Melanoma Treatment revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/acral-lentiginous-melanoma-treatment-market?sb

FAQ

Q: What is the growth rate of the Acral Lentiginous Melanoma Treatment Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 3% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us
-

Company
Name: DataM Intelligence

Contact Person: Sai Kiran

Email: Sai.k@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.